GI-101
- Generic Name
- GI-101
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
GI-101 is a bi-specific fragment crystallizable region (Fc) fusion protein containing a cluster of differentiation 80 ectodomain as an N-terminal moiety and interleukin-2 variant as a C-terminal moiety conjugated with human immunoglobulin G4 Fc.
- Associated Conditions
- -
- Associated Therapies
- -
GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- GI Innovation, Inc.
- Target Recruit Count
- 430
- Registration Number
- NCT04977453
- Locations
- 🇺🇸
Tisch Cancer Institute (TCI), Icahn School of Medicine, New York, New York, United States
🇺🇸Carolina Biooncology Institute, Huntersville, North Carolina, United States
🇰🇷The Catholic University of Korea St. Vincent's Hospital, Suwon-si, Kyeonggi-do, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath